Dazdotuftide:非感染性葡萄膜炎的新型治疗,眼压安全性更优:一项随机临床试验
这项3期随机双盲多中心活性对照试验评估了无类固醇抗炎药dazdotuftide(TRS01滴眼液)治疗活动性前部非感染性葡萄膜炎的安全性和有效性。研究纳入136例患者,随机2:1接受TRS01 1%或醋酸泼尼松龙1%每日4次治疗28天。结果显示TRS01在控制房水细胞方面劣于局部类固醇,但在控制 flare 和眼痛方面非劣效,且眼压安全性显著优于局部类固醇。
要点
- TRS01在第28天达到房水细胞分级0的比例为48%,低于醋酸泼尼松龙的68%。
- TRS01在控制flare和眼痛方面非劣效于局部类固醇。
- 对于达到房水细胞0的患者,TRS01的眼压安全性结局显著优于类固醇。
核心结论
- TRS01有望成为非感染性葡萄膜炎的有效且安全的治疗选择,可控制炎症而不伴类固醇相关的眼压升高风险。
研究设计与样本
- 随机、双盲、多中心、活性对照3期试验。
- 纳入成人(≤75岁)及儿童活动性前部非感染性葡萄膜炎患者,研究眼房水细胞分级为2级或3级。
- 患者按2:1随机接受TRS01 1%或醋酸泼尼松龙1%滴眼液,每日4次,治疗28天。
- 全分析集共136例患者,TRS01组平均年龄43岁,醋酸泼尼松龙组平均年龄42岁。
主要发现
- TRS01在控制房水细胞方面劣于局部类固醇,但在控制flare和眼痛方面非劣效于局部类固醇。
关键数值与推荐
- 主要结局指标包括第28天炎症消退(房水细胞分级=0)、房水细胞分级临床有意义改善、眼痛、flare和眼压变化。
- 入组标准:研究眼房水细胞分级为2级或3级(视觉模拟量表)。
临床怎么用
- TRS01可作为非感染性葡萄膜炎的控制炎症治疗选择,尤其适用于关注眼压升高风险的患者。
- 对于需要强效控制房水细胞的患者,TRS01的疗效劣于局部类固醇,临床决策需权衡炎症控制与眼压安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and efficacy of dazdotuftide (TRS01 eye drops), a novel, steroid-free, anti-inflammatory drug in patients with active anterior noninfectious uveitis (NIU), following previous studies in which it had shown a favorable risk/benefit profile with regards to safety and specifically intraocular pressure (IOP) safety profile. DESIGN: A randomized, double-masked, multicenter, active-controlled phase 3 trial. PARTICIPANTS: Adults (≤75 years of age) and pediatric patients, with active anterior NIU, with or without uveitic glaucoma, on stable medical therapy for NIU or who had received no prior therapy, requiring further treatment for an active NIU flare-up. Patients eligible for inclusion had Anterior Chamber Cell (ACC) Grade 2 or Grade 3 on Visual Analog Scale in the study eye. METHODS: Patients were randomized 2:1 to topical TRS01 1% or prednisolone acetate 1% administered 4 times daily for 28 days. Key ocular assessments included slit-lamp examination, ocular pain, Best Corrected Visual Acuity, IOP and dilated ophthalmoscopy. MAIN OUTCOME MEASURES: Resolution of inflammation (ACC = 0), clinically meaningful improvement of ACC, ocular pain, flare, and IOP changes on Day 28. RESULTS: The Full Analysis Set included 136 patients; the mean age was 43 years in the TRS01 arm and 42 years in the prednisolone acetate arm. 48% of TRS01 vs 68% of prednisolone acetate patients achieved ACC Grade = 0 on Day 28 (95.1% Confidence Interval (CI): -0.37, -0.02; P = .0311) and 64% of TRS01 vs 89% prednisolone acetate patients experienced clinically meaningful improvement of ACC Grade = 0 or 1, ie, ≤5 cells (95.1% CI: -0.33, -0.06; P = .0049). While TRS01 was found to be inferior to topical steroids to control ACC, TRS01 was noninferior to topical steroids to control flare and ocular pain and exhibited a superior IOP safety compared to topical steroids. For patients who reached ACC = 0, TRS01-treated patients benefited from statistically significantly improved safety outcomes for IOP (including change from baseline and at each IOP threshold evaluated [P < .05]) versus steroid-treated patients. CONCLUSIONS: TRS01 offers the potential to serve as an effective and safe treatment option in NIU that meets the urgent need for a drug that controls inflammation without the steroids' associated risk of IOP elevation.
引用
- Chu DS, Tsui E, Rifkin LM, et al. Dazdotuftide: Novel Treatment for Noninfectious Uveitis with Superior Intraocular Pressure Safety Profile: A Randomized Clinical Trial. Am J Ophthalmol. 2026. PMID: 41485727. doi:10.1016/j.ajo.2025.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。